Her Healthy Body flags 60-70% regain

GLP-1 weight loss is the easy part of this story. The hard part is what happens after the injections stop. That’s what the Her Healthy Body podcast zeroed in on in its May 4 episode — not just the headline that weight can come back, but the uglier detail that some of what people lose on these drugs is muscle, and that regain can happen fast if there’s no plan underneath it. (ivoox.com) ### What did the podcast actually flag? The episode itself was framed around body composition, not a fresh clinical study. The hosts talked through a familiar pattern in the GLP-1 era: women see the scale move, but without enough protein and resistance training, they may lose lean mass along with fat, feel weaker, and struggle to hold onto results l(ivoox.com)rk?” to “What happens when people stop, and what exactly did they lose on the way down?” (ivoox.com) ### Where does the 60% number come from? It’s not just social-media shorthand. A 2026 systematic review in *eClinicalMedicine* modeled the trajectory after GLP-1 receptor agonists are stopped and estimated that about 60% of the weight lost during treatment is regained within 1 year of cessation. That is basically the cleanest match for the stat attached to the episode. (thelancet.com) ### Is there a real-world monthly regain estimate? Yes — and it’s close to the number circulating around the episode. Oxford researchers said in January 2026 that across newer medicines such as semaglutide and tirzepatide, regain averaged about 0.8 kg per month after stopping. They also projected that, at that pace, many people would drift back toward baseline in roughly 1.5 years, though data beyond 12 months is still thinner than people would like. (ox.ac.uk) ### Have trials actually shown this? Yes. The classic semaglutide example is the STEP 1 extension. After stopping semaglutide 2.4 mg, participants regained about two-thirds of their prior weight loss within a year, and many cardiometabolic improvements moved back toward baseline too. Tirzepatide tells a similar story in SURMOUNT-4: people switched to placebo regained 14.0% of body weight over 52 weeks, while people who stayed on treatment kept losing. (europepmc.org) ### Why is this happening? Because these drugs are not just “motivation in a pen.” They suppress appetite and change the biology that was helping keep weight down. Once that effect is gone, hunger, food noise, and the body’s usual drive to restore lost mass can come roaring back. The Oxford team’s basic point was that this rebound is faster after stopping drugs than after ending behavioral progra(europepmc.org)willpower, is doing the heavy lifting here. (ox.ac.uk) ### Why does muscle keep coming up? Because the scale does not tell you what you lost. If part of the loss was lean mass, the person may end up lighter but also weaker, with lower energy needs and less room for error when appetite returns. The podcast’s advice — high protein and resistance training — is basically an attempt to protect the part of the body you want to keep while the drug helps reduce the part you want to lose. (ivoox.com) ### Why is this becoming a bigger issue now? Because lots of people discontinue treatment. A 2025 JAMA Network Open cohort study of 125,474 US adults found that within 1 year, 46.5% of patients with type 2 diabetes and 64.8% without diabetes discontinued GLP-1 drugs. Weight regain was also linked to restarting therapy. In other words, this is not a niche edge case — stopping is common. (jamanetwork.com) ### Are health systems reacting? Slowly, but yes. NICE in the UK added a quality standard in August 2025 saying people stopping weight-management medicines should get advice and support afterward, with at least a year of follow-up. That’s a pretty direct acknowledgment that the treatment problem does not end when the prescription does. (nice.org.uk)nes-for-weight-management-or-completing-behavioural-interventions)) ### Bottom line? The podcast’s core warning holds up. The flashy part of GLP-1s is the weight loss. But the real test is maintenance — and the evidence now says that without long-term treatment or a serious off-ramp plan, regain is common, fast, and biologically unsurprising. (ox.ac.uk)